Catalyst Pharmaceutical CPRX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Catalyst Pharmaceutical (CPRX) Core Market Data and Business Metrics
Latest Closing Price
$24.46Price-Earnings Ratio
18.67Total Outstanding Shares
121.45 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
355 Alhambra Circle, Coral Gables, FL, 33134
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,186,758 Shares | 6.09 | 3/14/2025 | 7,232,025 Shares |
| 1,262,345 Shares | 4.94 | 2/28/2025 | 6,230,963 Shares |
| 868,630 Shares | 6.58 | 2/14/2025 | 5,718,346 Shares |
| 1,365,560 Shares | 3.92 | 1/31/2025 | 5,354,514 Shares |
| 1,589,189 Shares | 4.17 | 1/15/2025 | 6,625,919 Shares |
| 848,986 Shares | 7.86 | 12/31/2024 | 6,676,769 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $239.81 Million |
| Net Cash Flow From Operating Activities, Continuing | $239.81 Million |
| Net Cash Flow From Financing Activities, Continuing | $140.66 Million |
| Net Cash Flow | $379.92 Million |
| Net Cash Flow From Investing Activities | $-556,000 |
| Net Cash Flow From Investing Activities, Continuing | $-556,000 |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Diluted Earnings Per Share | $1.31 |
| Diluted Average Shares | $124.94 Million |
| Gross Profit | $422.89 Million |
| Research and Development | $12.65 Million |
| Basic Average Shares | $118.46 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $163.94 Million |
| Comprehensive Income/Loss | $163.94 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $50,000 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $851.41 Million |
| Current Liabilities | $120.68 Million |
| Accounts Payable | $16.59 Million |
| Inventory | $19.54 Million |
| Noncurrent Assets | $227.80 Million |
| Equity | $727.63 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||